Legend Biotech CARVYKTI Sales Hit $334M
Ticker: LEGN · Form: 6-K · Filed: Jan 22, 2025 · CIK: 1801198
| Field | Detail |
|---|---|
| Company | Legend Biotech Corp (LEGN) |
| Form Type | 6-K |
| Filed Date | Jan 22, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $334 million |
| Sentiment | bullish |
Sentiment: bullish
Topics: sales-update, pharmaceutical, collaboration
TL;DR
Legend Biotech's CARVYKTI® raked in $334M last quarter, beating expectations.
AI Summary
Legend Biotech Corporation announced on January 22, 2025, that its drug CARVYKTI® generated approximately $334 million in net trade sales for the quarter ended December 31, 2024. This figure is based on information provided by Janssen Biotech, Inc., pursuant to their collaboration agreement.
Why It Matters
This sales figure indicates the market reception and commercial success of CARVYKTI®, a key revenue driver for Legend Biotech.
Risk Assessment
Risk Level: low — The filing is a routine sales update and does not contain new material risks.
Key Numbers
- $334M — CARVYKTI® Net Sales (For the quarter ended December 31, 2024)
Key Players & Entities
- Legend Biotech Corporation (company) — Registrant
- CARVYKTI® (product) — Drug
- $334 million (dollar_amount) — Net trade sales for Q4 2024
- December 31, 2024 (date) — End of reporting quarter
- January 22, 2025 (date) — Date of announcement
- Janssen Biotech, Inc. (company) — Collaboration partner
- December 21, 2017 (date) — Date of collaboration agreement
FAQ
What was the total net trade sales for CARVYKTI® in the quarter ended December 31, 2024?
CARVYKTI® generated approximately $334 million in net trade sales for the quarter ended December 31, 2024.
Who provided the sales information to Legend Biotech?
The sales information was provided by Janssen Biotech, Inc.
What is the date of this Form 6-K filing?
The filing date is January 22, 2025.
Under what agreement are these sales reported?
The sales are reported pursuant to the Collaboration and License Agreement dated as of December 21, 2017, between Legend Biotech Corporation and Janssen Biotech, Inc.
What is Legend Biotech Corporation's principal executive office address?
Legend Biotech Corporation's principal executive office is located at 2101 Cottontail Lane, Somerset, New Jersey 08873.
Filing Stats: 730 words · 3 min read · ~2 pages · Grade level 18.7 · Accepted 2025-01-22 07:30:38
Key Financial Figures
- $334 million — CARVYKTI ® generated approximately $334 million in net trade sales during the quarter e
Filing Documents
- f6k_012125.htm (6-K) — 12KB
- 0001171843-25-000360.txt ( ) — 13KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LEGEND BIOTECH CORPORATION Date: January 22, 2025 By: /s/ Ying Huang Name: Ying Huang, Ph.D. Title: Chief Executive Officer